International medical imaging company Sectra has finalized its acquisition of Oxipit, a Vilnius-based pioneer in artificial intelligence for radiology. The deal, completed on April 15, 2026, integrates Oxipit's advanced autonomous AI solutions into Sectra's extensive portfolio. This strategic move significantly enhances Sectra's capabilities in a market grappling with increasing diagnostic workloads and radiologist shortages.
A New Dimension in Diagnostic AI
The acquisition brings Oxipit's flagship product, ChestLink, under Sectra's ownership, marking a significant expansion of its AI offerings. ChestLink is distinguished as one of the first solutions to receive CE Class IIb certification for autonomous chest X-ray analysis. This regulatory approval underscores the product's reliability and safety, positioning it as a clinically validated tool ready for wider deployment.
Sectra has confirmed its commitment to the continued development and enhancement of the ChestLink platform. This addition provides Sectra with a market-ready autonomous AI product, complementing its existing vendor-neutral AI marketplace. The move signals a deeper investment into AI that can independently perform diagnostic tasks, rather than merely assisting clinicians.
The Power of Autonomous Analysis
Unlike conventional AI tools that support radiologists by flagging potential findings or prioritizing cases, autonomous AI operates differently. It is designed and validated to independently complete specific diagnostic tasks without direct human oversight for every case. This represents a paradigm shift in how AI is leveraged within clinical workflows to maximize efficiency and accuracy.
Oxipit's ChestLink exemplifies this technology by automatically identifying and clearing chest X-rays that show no abnormalities. This process removes a significant volume of normal scans from the radiologist's worklist, a crucial time-saving measure. Consequently, it allows highly skilled radiologists to dedicate their focus to more complex cases that have a higher probability of disease.
Addressing Critical Healthcare Challenges
Torbjörn Kronander, President and CEO of Sectra, emphasized the acquisition's strategic importance in addressing industry pressures. He noted that adding autonomous AI provides a genuine method to reduce the daily workload for radiologists. This is critical as healthcare systems worldwide face rising imaging volumes and persistent challenges with staff burnout.
The integration of Oxipit's technology and regulatory expertise is designed to help Sectra deploy this category of AI responsibly and at scale. Kronander highlighted that this acquisition, combined with Sectra's other innovations, demonstrates clear leadership in diagnostic imaging AI. The ultimate goal is to help healthcare providers manage their operational challenges more effectively.
Future Integration and Market Outlook
With the deal now closed, the focus shifts to integrating Oxipit's solutions within Sectra's ecosystem. The acquisition provides Sectra not just with a product but also with the specialized expertise required for developing and validating autonomous AI. This knowledge is invaluable for future innovation and for navigating the complex regulatory landscape of medical devices.
The successful deployment of ChestLink at scale could set a new standard for efficiency in radiology departments globally. By automating the review of normal scans, hospitals can improve turnaround times and better allocate their specialist resources. This strategic enhancement to Sectra's portfolio strengthens its position as a key partner for healthcare providers seeking advanced technological solutions.
Sectra's acquisition of Oxipit represents a pivotal moment for the medical imaging industry, signaling a firm commitment to the future of autonomous AI. By incorporating a clinically validated and regulatory-approved solution, Sectra is poised to deliver significant value to healthcare systems under pressure. This strategic investment not only enhances its product offerings but also reinforces its leadership in driving innovation to solve real-world clinical challenges.